CI Global Health Sciences Corporate Class

Series A USD
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date July 1996
CAD Total net assets ($CAD)
As at 2026-08-31
$250.9 million
NAVPS
As at 2026-09-30
$40.5157
MER (%)
As at 2026-03-31
2.34
Management fee (%) 1.90
Asset class Sector Equity
Currency USD
Minimum investment $500 initial/$25 additional
Distribution frequency Quarterly
Last distribution $0.7240

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

A ISC 301
DSC SO* 401
LL SO 1401
F 324
P 90324
*No new purchases directly into switch only funds.

Performance2 As at 2026-09-30

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
5.93% 3.51% 11.40% 5.83% 19.53% 3.11% -0.63% 2.73% 7.37%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.7240
2021-03-26 0.2492
2020-12-18 0.3973
2020-09-25 0.3778
2020-06-26 0.2765
Payable date Total
2020-03-20 0.6464
2019-12-13 0.4049
2019-09-27 0.4529
2019-06-21 0.4275
2019-03-22 0.6736

Management team

First we'll display the Team Company and then the Team members
Matthew Strauss

CI Global Health Sciences Corporate Class

Series A USD
 
Portfolio allocations4 As at 2026-08-31
Asset allocation (%)
  • US Equity 78.76
  • International Equity 17.03
  • Canadian Corporate Bonds 2.22
  • Cash and Equivalents 2.00
  • Other -0.01
Sector allocation (%)
  • Healthcare 91.81
  • Exchange Traded Fund 3.59
  • Fixed Income 2.22
  • Cash and Cash Equivalent 2.00
  • Other 0.38
Geographic allocation(%)
  • United States 78.29
  • Switzerland 7.09
  • United Kingdom 5.99
  • Netherlands 3.97
  • Canada 3.66
  • Europe 0.61
  • Other 0.38
  • Denmark 0.01
Top holdings6
Sector (%)
1. Eli Lilly and Co Drugs 9.04%
2. Johnson & Johnson Drugs 7.71%
3. UnitedHealth Group Inc Healthcare Services 7.09%
4. Thermo Fisher Scientific Inc Healthcare Equipment 6.44%
5. AbbVie Inc Drugs 6.38%
6. AstraZeneca PLC Drugs 5.99%
7. Danaher Corp Healthcare Equipment 5.26%
8. IQVIA Holdings Inc Drugs 4.81%
9. Stryker Corp Healthcare Equipment 4.80%
10. Merck & Co Inc Drugs 4.68%
11. DexCom Inc Healthcare Equipment 4.50%
12. Abbott Laboratories Healthcare Equipment 4.09%
13. argenx SE Drugs 3.97%
14. SPDR S&P Biotech ETF (XBI) Exchange Traded Fund 3.59%
15. Novartis AG Cl N Drugs 3.30%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.